| Literature DB >> 34691413 |
Shaparak Najibi1, Mitra Modares Gilani2, Fatemeh Zamani3, Setare Akhavan2, Narges Zamani2.
Abstract
BACKGROUND: Various modalities including ultrasonography and magnetic resonance imaging (MRI) have been developed as imaging technique for screening malignant myometrial tumors, but a few studies assessed the diagnostic value of these two techniques in differentiation of benign from malignant myometrial tumors that had been the main purpose of this study.Entities:
Keywords: Cross sectional; Diagnostic value; MRI; Malignant myometrial tumors; Test accuracy; Ultrasonography
Year: 2021 PMID: 34691413 PMCID: PMC8519770 DOI: 10.1016/j.amsu.2021.102813
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
The association of pathological results with ultrasonography according to baseline parameters.
| Pathological malignancy (+) | Pathological malignancy (−) | Kappa value | |
|---|---|---|---|
| Before menopause | 0.276 | ||
| Positive malignancy | 10 (76.9%) | 3 (23.1%) | |
| Negative malignancy | 18 (46.2%) | 21 (53.8%) | |
| After menopause | 0.299 | ||
| Positive malignancy | 3 (100%) | 0 (0.0%) | |
| Negative malignancy | 6 (75.0%) | 2 (25.0%) | |
| With pain | 0.265 | ||
| Positive malignancy | 8 (80.0%) | 2 (20.0%) | |
| Negative malignancy | 11 (52.4%) | 10 (47.6%) | |
| Without pain | 0.260 | ||
| Positive malignancy | 5 (83.3%) | 1 (16.7%) | |
| Negative malignancy | 13 (50.0%) | 13 (50.0%) | |
| With bleeding | 0.115 | ||
| Positive malignancy | 5 (62.5%) | 3 (37.5%) | |
| Negative malignancy | 15 (48.4%) | 16 (51.6%) | |
| Without bleeding | |||
| Positive malignancy | 8 (100%) | 0 (0.0%) | |
| Negative malignancy | 9 (56.3%) | 7 (43.8%) |
The association of pathological results with MRI and ultrasonography findings (chi-square test).
| Pathological malignancy (+) | Pathological malignancy (−) | P value | |
|---|---|---|---|
| MRI | 0.0001 | ||
| Positive malignancy | 35 (94.6%) | 2 (5.4%) | |
| Negative malignancy | 2 (7.7%) | 24 (92.3%) | |
| Ultrasonography | 0.034 | ||
| Positive malignancy | 13 (81.3%) | 3 (18.8%) | |
| Negative malignancy | 24 (51.1%) | 23 (48.9%) |
The association of pathological results with MRI according to baseline parameters.
| Pathological malignancy (+) | Pathological malignancy (−) | Kappa value | |
|---|---|---|---|
| Before menopause | 1.000 | ||
| Positive malignancy | 26 (92.9%) | 2 (7.1%) | |
| Negative malignancy | 2 (8.3%) | 22 (91.7%) | |
| After menopause | 0.845 | ||
| Positive malignancy | 9 (100%) | 0 (0.0%) | |
| Negative malignancy | 0 (0.0%) | 2 (100%) | |
| With pain | 0.720 | ||
| Positive malignancy | 17 (89.5%) | 2 (10.5%) | |
| Negative malignancy | 2 (16.7%) | 10 (83.3%) | |
| Without pain | 1.000 | ||
| Positive malignancy | 18 (100%) | 0 (0.0%) | |
| Negative malignancy | 0 (0.0%) | 14 (100%) | |
| With bleeding | 0.950 | ||
| Positive malignancy | 20 (95.2%) | 1 (4.8%) | |
| Negative malignancy | 0 (0.0%) | 18 (100%) | |
| Without bleeding | 0.710 | ||
| Positive malignancy | 15 (93.8% | 1 (6.3%) | |
| Negative malignancy | 2 (25.0%) | 6 (75.0%) |